Skip to main content

Xortx Therapeutics Inc(XRTX-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low2.53
Day High3.60
Open:2.95
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
GlobeNewswire
XORTX Meets Nasdaq Continued Listing Requirements
Tipranks
XORTX Closes US$3 Million Acquisition of Vectus Kidney Anti‑Fibrotic Program
Tipranks
XORTX Closes US$3 Million Deal for Vectus Kidney Anti-Fibrotic Program
GlobeNewswire
XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset
Tipranks
XORTX Therapeutics Secures Exchange Approvals for 1-for-5 Share Consolidation Effective April 6
GlobeNewswire
XORTX Confirms Effective Date of Share Consolidation
Tipranks
XORTX Shareholders Approve Governance Measures and Share Consolidation at Annual Meeting
Tipranks
XORTX Delays Effective Date of One-for-Five Share Consolidation
Tipranks
XORTX Consolidates Shares in Bid to Maintain Nasdaq Listing
GlobeNewswire
XORTX Announces Results of Annual and Special Meeting of Shareholders
GlobeNewswire
XORTX Announces Change of Effective Date of Share Consolidation
GlobeNewswire
XORTX Announces Share Consolidation
Tipranks
XORTX Shareholders Approve Reverse Split to Preserve Nasdaq Listing
GlobeNewswire
XORTX Reports that Shareholders Approved the Share Consolidation at the Annual General Meeting
Tipranks
XORTX Ties Board Shake-Up to Financing Ahead of March 24 Shareholder Vote
Tipranks
XORTX Reshapes Board to Meet Conditions for Planned Financing
GlobeNewswire
XORTX Announces Substitute Director Nominees for its Upcoming Annual and Special Meeting of Shareholders
Tipranks
Proxy Advisers Back XORTX Share Consolidation Plan Ahead of March Vote
GlobeNewswire
XORTX Reports that Independent Proxy Advisory Firms Recommend XORTX Shareholders Vote “For” the Share Consolidation
Tipranks
XORTX Sets March 24 Shareholder Meeting, Puts Share Consolidation to a Vote
Tipranks
XORTX Sets March 24 Shareholder Meeting, Seeks Approval for Share Consolidation and Governance Matters
GlobeNewswire
XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders
Tipranks
XORTX Calls March 24, 2026 Shareholder Meeting to Vote on Share Consolidation and Governance Matters
Tipranks
XORTX Files 2025 Annual Financials as Auditors Flag Going‑Concern Risk
Tipranks
XORTX Extends Deadline for Vectus Renal Anti-Fibrotic Program Acquisition and Sets March Shareholder Meeting
GlobeNewswire
XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems
Tipranks
XORTX Highlights New Gout Genetics Research, Reshapes Board and Clarifies Financing as Vectus Deal Nears Closing
Tipranks
XORTX Leans Into Genetic Breakthroughs in Gout as It Reshapes Board and Advances Oxypurinol
GlobeNewswire
XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update
Tipranks
XORTX Therapeutics Reports Q3 2025 Financial Results
Tipranks
XORTX Therapeutics Completes $1.1 Million Direct Offering
Tipranks
XORTX Therapeutics Secures $1.1 Million in Direct Offering

Profile

XORTX Therapeutics Inc. is a pharmaceutical therapeutics company. It focused on developing therapies to treat progressive kidney disease. XORTX Therapeutics Inc. is based in CALGARY, Alberta.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.